Monash University researchers, along with industry partner Haemokinesis, have developed the world’s first blood incubator using laser technology.
Blood transfusions require matching recipients, and screening the blood beforehand using traditional methods can take a quarter of an hour.
The laser incubation technology reduces the delay before a blood transfusion from 15 minutes to 40 seconds, which substantially affects a patient’s chance of survival.
“Giving blood transfusions to people isn’t as simple as giving O-negative to anybody. The ‘universal donor’ of O-negative blood can seriously harm a lot of people, even kill them,” explains Dr Clare Manderson, a researcher from the Bioresource Processing Institute of Australia (BioPRIA), based at Monash University.
The current industry gold standard is five minutes.
The study shows that laser incubation can improve pre-transfusion testing for millions of patients undergoing blood transfusions across the world, especially those having major surgery, women in labour or casualties of mass trauma who need fast blood transfusions.
Additionally, the shorter turnaround time saves on pathology costs, according to Haemokinesis.
Dr Clare Manderson discussed how the incubator works with Innovation Intelligence.
“The laser-incubator heats the blood-antibody sample to 37°C in under 30 seconds and keeps it at that temperature plus or minus one degree, for however long it needs to be. The gel is removed and put into a centrifuge where it is spun, separated and the blood and anti-body sample pass through the gel.
“The results are indicated by the position of the red blood cells in the gel. In positive blood groups the red blood cells sit on top of the gel, in negative blood groups the red blood cells pass through the gel.
“In our paper we looked at lots of different incubation times and we’re able to show that 40 seconds is enough to get positive results,” Dr Manderson said.
With the blood laser incubator, no significant damage was detected to the cells or antibodies while maintaining the temperature up to this time.
Vaughn Davies, head of sales at Haemokinesis, adds that the solution also creates a digital archive of the results which can be referred to if necessary.
“Traditionally laboratories have used the test tube system, where there are no permanently recorded results. You drop your reagent in the test tube, put the patient’s blood cells in, spin it in the centrifuge for a minute, read your results, then throw the tubes away.
“If there is any doubt or any question about it, how do you know what the result was?” Davies said.
While the technology isn’t yet commercially available in Australia, Haemokinesis holds a patent for this innovation as well as a Therapeutic Goods Administration (TGA) licence and is in discussions with hospitals and pathology companies.
Haemokinesis is already
selling products
to distributors across South East Asia, and Europe.
The company also has commercialised a separate blood diagnostics tool called
GLIF
or in length: Group Legible Immunohaematology Format, which is a blood test that can be conducted by untrained individuals and performed out of curiosity.
“The world of pre-transfusion of blood group typing is huge, and it’s really important that it’s done quickly and accurately to help save lives,” Dr Manderson said.